|
Sep 12
|
Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock
|
|
Sep 12
|
Rocket Pharmaceuticals Reaches FDA Alignment on Pivotal Phase 2 Trial Design for RP-A501 in Danon Disease
|
|
Sep 6
|
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
|
|
Aug 10
|
Rocket Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Progress
|